Singapore: A phase III trial evaluating the efficacy and safety of the addition of Tarceva (erlotinib) tablets to Nexava...
Singapore: Researchers have begun enrolling participants in to a multicenter international clinical trial to test whethe...
Singapore: China's BeiGene, a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and im...
Tokyo: Intercept Pharmaceuticals Inc has announced the results of a 72-week phase II dose ranging trial of obeticholic a...
Pharmaceutical Product Development(PPD) and CISYS LifeSciences has announced PPD's implementation of Sequence WebEAS, a ...
Singapore: QPS Holdings, a leading full-service clinical research organization, announced the launch of its QPS Qualiti...
Singapore: Cellmid has completed its first in-life diabetic nephropathy study with the company's anti-midkine antibodie...
Singapore: Sanofi Pasteur, the vaccines division of Sanofi has published clinical study results of its dengue vaccine ca...
Singapore: At a recent Pharma CI Conference & Exhibition Asia held in Tokyo, Citeline, a leading research authority ...
Singapore: According to reports, Quest Life Sciences has received a 'notice of concern', or NoC from the World Health Or...
The Australian Medical Association (AMA) has welcomed a new register for clinical trials in the country for patients to ...
Tokyo: Chugai Pharma USA Inc. (CPUSA), a wholly-owned subsidiary of Japan's Chugai Pharmaceutical Co Ltd. has officially...
Singapore: OxOnc Development, an oncology development company founded by pharmaceutical development executives and oncol...
Singapore: Medidata, a provider of cloud-based solutions for clinical research, has collaborated with Japan Pharmaceutic...
When drugs are trialed in patients, they move into a clinical setting in which the busy routine care of patients, rath...
Tokyo: New Jersey-headquartered Catalent Pharma Solutions, the leading global provider of advanced delivery technologies...
Australia's strong history of quality and experience in clinical research is well known, and whilst being a comparativ...
OxOnc Development LP has announced that Study OO-1201, a phase II open-label, single-arm study of crizotinib in East Asi...
